New hope for rare ovarian cancer patients after standard treatments fail

NCT ID NCT05348356

Summary

This study tested an experimental drug called nirogacestat in patients with a rare type of ovarian cancer (granulosa cell tumor) that had returned after prior treatment. The goal was to see if the drug could shrink tumors and control the disease. The trial enrolled 53 adults whose cancer had progressed despite other therapies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AdventHealth Orlando

    Orlando, Florida, 32804, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • David C. Pratt Cancer Center

    St Louis, Missouri, 63141, United States

  • Froedtert and Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Greater Baltimore Medical Center

    Baltimore, Maryland, 21204, United States

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

  • Jagiellonian Innovation Centre Clinical Research Centre

    Krakow, 30-348, Poland

  • Maria Sklodowska-Curie Bialystok Oncology Center

    Bialystok, 15-027, Poland

  • Maria Sklodowska-Curie National Institute of Oncology-National Research Institute, Clinic of Oncological Gynecology

    Warsaw, 02-781, Poland

  • Memorial Sloan Kettering Cancer Institute

    New York, New York, 10065, United States

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • Orlando Health Cancer Institute

    Orlando, Florida, 32806, United States

  • UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit

    Los Angeles, California, 90095, United States

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • UW/Fred Hutch Cancer Center

    Seattle, Washington, 98109, United States

  • University Teaching Hospital Poznan, Department of Oncological Gynaecology

    Poznan, 60-569, Poland

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico, 87102, United States

  • Women's Cancer Care

    Covington, Louisiana, 70433, United States

  • Women's Cancer Center at Kettering

    Kettering, Ohio, 45429, United States

Conditions

Explore the condition pages connected to this study.